XINGANJIANG
873167
INNOVATIVE DATA
835305
CHENGUANG MEDICAL
430300
4
Hangzhou Gaoxin Materials Technology
300478
5
Beijing Philisense Technology
300287
(FY)Dec 28, 2024 | (Q4)Dec 28, 2024 | (Q3)Sep 28, 2024 | (Q2)Jun 29, 2024 | (Q1)Mar 30, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jul 1, 2023 | (Q1)Apr 1, 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Total revenue | -1.99%2.71B | -1.69%640M | -0.43%689M | -4.00%672M | -1.81%707M | 2.52%2.76B | -3.84%651M | -1.84%692M | 1.45%700M | 720M |
Operating revenue | -1.99%2.71B | -1.69%640M | -0.43%689M | -4.00%672M | -1.81%707M | 2.52%2.76B | -3.84%651M | -1.84%692M | 1.45%700M | --720M |
Cost of revenue | -4.68%1.92B | -5.38%440M | -0.20%495M | -6.48%476M | -6.67%504M | -2.66%2.01B | -9.00%465M | -6.59%496M | -2.49%509M | 540M |
Gross profit | 5.17%793M | 7.53%200M | -1.02%194M | 2.62%196M | 12.78%203M | 19.49%754M | 12.05%186M | 12.64%196M | 13.69%191M | 180M |
Operating expense | -4.68%631M | -1.21%163M | -9.50%162M | -8.59%149M | 0.64%157M | 19.06%662M | -5.17%165M | 7.19%179M | 27.34%163M | 156M |
Selling and administrative expenses | -4.68%631M | -1.21%163M | -9.50%162M | -8.59%149M | 0.64%157M | 19.06%662M | -5.17%165M | 7.19%179M | 27.34%163M | --156M |
Operating profit | 76.09%162M | 76.19%37M | 88.24%32M | 67.86%47M | 91.67%46M | 22.67%92M | 362.50%21M | 142.86%17M | -30.00%28M | 24M |
Net non-operating interest income expense | -200.00%-30M | 30.00%-7M | -7M | -8M | -8M | -10M | -10M | 0 | 0 | 0 |
Non-operating interest expense | 200.00%30M | -30.00%7M | --7M | --8M | --8M | --10M | --10M | --0 | --0 | --0 |
Other net income (expense) | -174.60%-47M | -270.00%-17M | -205.26%-40M | -42.86%4M | -25.00%6M | 162.38%63M | 105.56%10M | 72.73%38M | -75.00%7M | 8M |
Special income (charges) | ---53M | ---15M | ---38M | ---- | ---- | ---- | ---- | --0 | ---- | ---- |
-Less:Restructuring and merger&acquisition | --53M | --15M | --38M | ---- | ---- | ---- | ---- | --0 | ---- | ---- |
Other non- operating income (expenses) | -90.48%6M | -120.00%-2M | -105.26%-2M | -42.86%4M | -25.00%6M | 162.38%63M | 105.56%10M | 72.73%38M | -75.00%7M | --8M |
Income before tax | -41.38%85M | -38.10%13M | -127.27%-15M | 22.86%43M | 37.50%44M | 657.69%145M | 111.17%21M | 89.66%55M | -48.53%35M | 32M |
Income tax | -62.86%13M | -200.00%-6M | -130.77%-4M | 50.00%12M | 37.50%11M | 3,600.00%35M | 116.67%6M | 116.67%13M | -46.67%8M | 8M |
Net income | -34.55%72M | 26.67%19M | -126.19%-11M | 14.81%31M | 37.50%33M | 540.00%110M | 109.87%15M | 82.61%42M | -49.06%27M | 24M |
Net income continuous Operations | -34.55%72M | 26.67%19M | -126.19%-11M | 14.81%31M | 37.50%33M | 540.00%110M | 109.87%15M | 82.61%42M | -49.06%27M | --24M |
Minority interest income | ||||||||||
Net income attributable to the parent company | -34.55%72M | 26.67%19M | -126.19%-11M | 14.81%31M | 37.50%33M | 540.00%110M | 109.87%15M | 82.61%42M | -49.06%27M | 24M |
Preferred stock dividends | ||||||||||
Other preferred stock dividends | ||||||||||
Net income attributable to common stockholders | -34.55%72M | 26.67%19M | -126.19%-11M | 14.81%31M | 37.50%33M | 540.00%110M | 109.87%15M | 82.61%42M | -49.06%27M | 24M |
Basic earnings per share | -35.16%0.83 | 22.22%0.22 | -126.53%-0.13 | 17.30%0.37 | 36.17%0.38 | 540.32%1.28 | 110.18%0.18 | 83.22%0.49 | -48.82%0.3154 | 0.2791 |
Diluted earnings per share | -35.94%0.82 | 16.67%0.21 | -126.53%-0.13 | 14.13%0.36 | 32.58%0.37 | 540.32%1.28 | 110.18%0.18 | 83.22%0.49 | -48.82%0.3154 | 0.2791 |
Dividend per share | 300.00%0.64 | 0.00%0.16 | 0.16 | 0.16 | 0.16 | 0.16 | 0.16 | |||
Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
Audit Opinions | -- | -- | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- |